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The etiology of childhood cancers has been studied for more than 40 years. However, most if not all cancers
occurring in children are attributed to unknown causes. This review is focused on the role of infections in cancer
development and progression in children. The main infectious agents include human herpesviruses, polyoma
viruses, and human papilloma viruses. It is known that infections can lead to carcinogenesis through various
mechanisms, and most likely act in addition to genetic and environmental factors. Given the importance of the
infectious etiology of childhood cancers, clinical implications and possible prevention strategies are discussed.
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Cancer is the second leading cause of death in children
under 15 years of age. Childhood cancers (CC) include a
variety of malignant tumors. Annual incidence world-
wide is approximately 160,000 cases per year, whereas
mortality rates average 90,000 [1]. Leukemia is diagnosed
in about 30 − 34% of all CC [1]. Acute lymphoblastic
leukemia (ALL) and acute myeloblastic leukemia (AML)
are the two most frequent types of leukemia found in
children [1]. The former occurs approximately five times
more frequently than the latter, and accounts for ap-
proximately 75% of all childhood leukemia cases [1].
Central nervous system (CNS) cancers are the second
most frequent in pediatric oncology, accounting for
about 27% of CC [2]. The occurrence of CNS tumor
types in children differs by type, with 30% low-grade gli-
oma, 25% medulloblastoma, 20% high-grade glioma,
10% atypical teratoid/rhabdoid tumor, and 15% other
CNS tumors [3]. Lymphomas represent the next most
common type of CC, averaging 15% [4]. According to
the National Cancer Institute, Hodgkin’s lymphoma
(HL) accounts for 4 − 6% of all childhood cancers, with
the highest incidence rates in 15–19 year olds [2]. Non-
Hodgkin’s lymphomas (NHL) account for 6 − 7% of all* Correspondence: akakpenova@nu.edu.kz
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most frequent subtypes, Burkitt’s lymphoma (BL), lympho-
blastic lymphoma (LL), diffuse large B-cell lymphoma
(DLBCL), and anaplastic large cell lymphoma (ALCL) [4].
There are other subtypes of childhood NHL, but they ac-
count for less than 5% of all cases. Incidence statistics for
soft tissue cancers is around 9%, whereas for bone cancers
(including osteosarcoma and Ewing’s sarcoma) the inci-
dence is 6% [2]. Neuroblastoma is diagnosed in 7% of the
CC cases, nephroblastoma (Wilms) tumors occurs in 5%
and retinoblastoma in 3% CC cases [2].
Cancers found in children are usually quite distinct
from those seen in adults. Because the causes of child-
hood cancers are unknown, it is difficult to determine a
specific mechanism. This may be due to different expo-
sures to environmental hazards/infectious agents coupled
with immature physiological systems, as well as vulner-
ability at critical developmental stages [5]. In this review,
we address the possible role of infectious agents in the on-
set and progression of childhood tumors.
Our search strategies included a background literature
review, then systematic analysis and all-round discussion
of found information on childhood cancers, risk factors
and mechanisms of infectious agents. General and ad-
vanced search via the most comprehensive scientific da-
tabases on life sciences and biomedical topics, such as
MEDLINE and SpringerLink, were used to conduct effect-
ive literature review. The search specifications narrowedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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types to “Review, clinical, trials, meta-analyses, and case
reports”. Reference lists were thereafter hand-searched for
additional articles. Then the full text articles were ob-
tained and analyzed for actuality and authenticity of
information.
Possible causes and risk factors
To date, in addition to inherited factors, the World
Health Organization (WHO) classifies four different
groups of external agents as carcinogens which cause
cancer in children. These are physical, biological, chem-
ical carcinogens, and dietary components (e.g., cured
meats) [5].
Extensive data is now available on known and sus-
pected risk factors for childhood cancers, including but
not limited to: early-life exposures to infectious agents
(viruses, bacteria, protozoa, and fungi); parental, fetal, or
childhood exposures to environmental toxins (pesticides,
solvents, and household chemicals); parental occupa-
tional exposures to radiation or chemicals; parental
medical conditions during pregnancy or before concep-
tion; maternal diet during pregnancy; early postnatal
feeding patterns and diet; maternal reproductive history,
and familial and genetic susceptibility; and risk associ-
ated with exposure to HIV[5]. Genetic risk factors usu-
ally include familial aggregations of genetic syndromes
such as retinoblastoma, Li-Fraumeni syndrome, heredi-
tary nonpolyposis colon cancer, ataxia telangiectasia, and
others [6].
However, there are still no definitive causes identified
for CC. In general, in 5 − 15% of CC cases genetic factors
are thought to predispose the child to the development
of cancer [7]. Environmental and exogenous factors have
much lower figures (5 − 10%), leaving the vast majority
of CC (75 − 90%) poorly understood and of unknown
causes [8,9]. Because cancer is a multifactorial disease
caused by genetic and environmental factors, it is often
difficult to determine the critical period of exposure as
during pregnancy or earlier [9]. In addition, childhood
cancers develop and manifest differently from one another
due to multiple numbers of causes and distinctive clinical
courses with respect to age, ethnicity, and gender [10].
Role of infections in etiology of childhood cancers
Leukemia
Two models have been proposed to explain how infec-
tious agents could play a role in the development of
childhood leukemia. The first model relies on the direct
transforming ability of transforming viruses. Secondly,
the effect might be due to the problems caused by ab-
normal immunological responses to congenital, neonatal,
or post-neonatal infections, which in turn promote sec-
ondary genetic or immunological alterations. In thiscase, the action of microorganisms may be indirect and
non-transforming (reviewed in [11]). One of the main
agents in the proposed infectious association with child-
hood leukemia is a group of human herpesviruses, espe-
cially Epstein-Barr virus (EBV) and human herpesvirus 6
(HHV-6).
Associations of EBV with childhood leukemia, mainly
lymphoblastic leukemia (ALL), have been found in some
seropositivity studies, genetic analyses, and epidemio-
logical studies. Initially it was shown [12] that EBV viral
capsid antigen (VCA) IgM, in EBV-seropositive mothers,
was associated with increased risk of acute ALL in off-
spring. In addition, Z Epstein-Barr replication activator
(ZEBRA) IgG and VCA IgM antibody associations were
attributed to increased risk of non-ALL in offspring.
However the statistical significance of the results was
not confirmed by a larger study of the same group [13].
The presence of VCA antibodies is recognized as a sen-
sitive measurement for active infection. While for EBV
reactivation, testing for ZEBRA and for EBV early anti-
gen antibody was found to be useful. In addition,
ZEBRA IgG and VCA IgM antibody associations were
attributed to increased risk of non-ALL in offspring.
EBV ZEBRA protein interacts with mitotic chromo-
somes, and with p53 and promyelocytic leukemia pro-
teins. This might suggest a proposed mechanism for the
transforming activity of the virus. Recent DNA studies
show that latent membrane protein 1 of the EBV gene
transcripts was found in 29/80 of the cancer cases versus
0 in the control group, in cases of ALL, AML, and
chronic myelogenous leukemia (CML) [14]. ZEBRA pro-
tein transcripts and active EBV replication was detected
by PCR and western blot in ALL patients. In the study
positive controls (patients with Burkitt’s lymphoma and
infectious mononucleosis) were consistently positive, but
healthy donors, other disease controls, cases of AML
and multiple myeloma showed negative results [15].
There are several mechanisms by which EBV could in-
crease the risk of malignant transformation of infected
cells. It was found that viral proteins inhibit apoptosis
[16-18], affect the JAK/STAT pathway [19-22], promote
epigenetic changes [23-25], and undermine the immune
defense mechanisms [26] (see Table 1 for details).
Information has been reported on possible roles of
HHV-6 in leukemia development (reviewed in [35]).
HHV-6 was first isolated from patients with lymphopro-
liferative disorder. Arbuckle et al. [36] showed that
HHV-6 antibody level was increased in children with
ALL, but a subsequent study showed no significant dif-
ference (50 patients/50 controls). Slight but significant
serological correlation was shown in case control studies
with AML. The presence of HHV-6 IgM in 40% of chil-
dren with leukemia, and high avidity of IgG compared
with controls was shown in further studies. HHV-6
Table 1 Possible carcinogenic mechanisms of viruses implicated in childhood cancers
Virus and its product Mechanism Reference
Inhibition of apoptosis
- EBV
➢ EBNA-1 - Related to BCL2 [16]
➢ BHRF1, BALF1 - Related to BCL2 [17]
➢ EBNA3A, 3C - Inhibit Bim [18]
- CMV
➢ IE1, IE2 - Inhibit apoptosis by activating PI3K pro-survival pathway [27,28]
➢ UL36 - Confers resistance to chemotherapy in neuroblastoma [29]
Disruption of signaling pathways/autonomous growth
- HHV-6 (U95) - U95 binds NF-kB, probably deregulating the pathway [30]
- EBV - JAK/STAT pathway implicated L6 released by macrophages surrounding nasopharyngeal
epithelial cells, binds to its receptor and activates STAT3, which triggers transcription of its
target genes (cyclin D1, Bcl-xL, c-myc, survivin, VEGF). A correlation of VEGF expression as a
key angiogenic factor in NPC metastasis is supported.
[19-21]
[22]
- SV40 - Activation of growth factors and autocrine growth of mesothelioma cells, while RASSF1 is inactivated [31]
Ablation of tumor-suppressors p53: viral proteins bind and thereby inactivate the tumor suppressors
- HPV 16/18 (E6, E7) - Bind and inactivate p53 [32]
- BKV - BKV is present in neuroblastomas, and colocalizes to p53. [33]
- HHV-6 (U14 and ORF-1) - Bind and inactivate p53 [30]
Promotion of epigenetic changes/RNA interference
- EBV - EBV-infected cells acquire extensive methylation to silence multiple tumor suppressor genes. [23]
➢ LMP1 - LMP1 downregulates CDH1 0.2-fold through upregulation of DNMT1, DNMT3A, DNMT3B, and 3-8-fold in
NPC076 NPC cell line.
[24]
➢ miR-BART5 - Downregulation of PUMA expression in EBV-positive NPC and gastric carcinoma cells; decreasing levels
of miR-BART5 or expression of PUMA can revert the suppression of apoptosis.
[25]
Suppression and evasion of the immune system
- CMV - Inhibit expression of HLA class I and II antigens and antigen presentation, thus activation of T-cells [34]
- EBV (EBNA-1) - Cells expressing EBNA-1 do not present sufficient quantities of EBNA1 peptide on MHC class I. [26]
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T-cell ALL. Importantly, a direct transforming ability of
HHV-6 was shown in vitro with 3T3 cells and human
epidermal keratinocytes. HHV-6 also has a unique ability
to integrate viral DNA into chromosomes. Chromo-
somal transmission of HHV-6 DNA was shown in ALL
cells in culture (reviewed in [35]). Apart from integration
into chromosomal DNA, HHV-6 protein products are
also able to interfere with host protein functions. U95
binds to NF-kB, altering the pathway, and U14 and
ORF-1 bind and inactivate p53 [30]. These interactions
likely contribute to the oncogenic transformation of in-
fected host cells. Overall, although the results of studies
showing the presence of serum antibodies to HHV-6 or
viral DNA remain controversial, there is a possibility
that HHV-6 can act via chromosomal integration and/or
by the direct transforming ability of the virus.
Antibodies against herpes simplex, another member of
the Herpesviridae, were prevalent in children with ALL
in Iran. Patients had higher values of antibodies againstHSV1 IgG (82.2%) comparing to a control group of 90
age-sex matched healthy children (54.5%) [37]. Other in-
fectious agents associated with childhood leukemia in-
clude hepatitis B virus, human T-cell lymphoma virus I,
and parvovirus B19. Although association with certain
infectious agents is known, analysis of the presence of
exogenous genomes in leukemia cells suggests that a sin-
gle transforming agent is unlikely to cause leukemia de-
velopment [11]. The mechanism for cancer development
will probably involve several factors, wherein infectious
agents can act as triggering factors.
Lymphoma
HL can be divided into two subtypes, EBV-associated
and non-EBV-associated HL. Approximately 40 − 45% of
the cases can be attributed to EBV infections, with high
prevalence found in children under the age of 10 years.
This could be associated with primary infections in
younger children, and to loss of immune surveillance in
older adults [38-40]. Evidence of an associations of HL
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vated titers of anti-EBV antibodies in HL patients [39,40].
In addition, the presence of viral DNA was demonstrated
in malignant HL or Reed-Sternberg cells, where it estab-
lished latency type II through the expression of Epstein-
Barr nuclear antigen 1 (EBNA1), latent membrane protein
1 (LMP1), and latent membrane protein 2A (LMP2A)
proteins [40,41].
There are three clinical variant types of BL, endemic,
sporadic, and HIV-associated types. In all cases, tumor
cells are characterized by c-myc oncogene translocation
and differing positivity for EBV [42]. Endemic BL com-
prises up to 75% of all childhood cancers in malaria en-
demic areas, and are EBV positive in almost 100% of the
cases. HIV-associated BL patients are positive for EBV in
one third of all cases [41,42]. This finding suggests that
BL is a polymicrobial disease [43], where malaria or HIV
antigens act as co-agents in BL pathogenesis [44].
Although mucosa-associated lymphoid tissue (MALT)
NHL occurs very rarely in children, it is noteworthy that
its development is also associated with infection. The
presence of H. pylori is demonstrated in almost all cases
of MALT lymphoma [39,40,45]. Approximately half of
the reported pediatric MALT lymphoma cases were ob-
served in HIV positive patients [46,47]. Eradication of H.
pylori with antibacterial therapy could lead to eradica-
tion and/or remission of the associated malignancy in
most adult and pediatric cases [39,40,45,46].
Nervous system tumors
Nervous system tumors occur frequently in children, es-
pecially CNS tumor that is the second most common
pediatric cancer. There are many types of nervous sys-
tem tumors, and they occur at different ages. Neuro-
blastoma can be diagnosed prenatally or during the first
3 months of life. Astrocytomas are often diagnosed at 5
to 13 years of age, while primitive neuroectodermal tu-
mors (PNET) and ependymomas are common at 3 years
of age, and decline as age increases [48,49]. However,
there is no known cause of nervous system cancer.
Whether there is a genetic polymorphism which is cru-
cial in a particular tumor type, or an involvement of
toxins that regulate cell types at different stages of devel-
opment remains unknown [50]. The very early onset of
the disease suggests that parental factors may play a role
during the period prior to conception, during gestation,
or at birth [51]. It was reported that the children of
mothers who had a documented viral infection during
pregnancy had an 11-fold increased risk of having a ma-
lignant nervous system tumor. The infections linked to
risk included rubella, mumps, varicella zoster, influenza,
and herpes and respiratory infections [52,53].
Polyomaviruses Simian virus 40 (SV40), John Cunningham
virus (JCV), and BK are suspected to cause variousoncological malignancies. These viruses were introduced
into the human population in the 1950s [54] and SV40
was suspected to cause brain tumors [55]. Later retro-
spective studies found no correlation of SV40 contami-
nated vaccines with brain cancer [56,57]. However, later
reports found that the viruses were positively correlated
with CNS tumors in adults and children [58,59].
The presence of JCV in pediatric tumors was detected
by immunohistochemistry, PCR, and Southern blot,
using T antigen and agnoprotein markers, but different
laboratories found a discrepancy in results [60]. In 62
cases of various pediatric CNS tumors (medulloblas-
toma, ependymoma, choroid plexus papilloma, and pilo-
cytic astrocytoma) the viral DNA was found in 28% of
the ependymomas, and in 20% of the choroid plexus
papillomas [61]. In a 9-year-old patient diagnosed with
pleomorphic xanthoastrocytoma, the genomic sequences
of JCV LT, R, and VP1 were detected [62]. Further cases
of JCV in pediatric pleomorphic xanthoastrocytoma were
not reported.
A member of polyomaviruses BK is implicated in ner-
vous system carcinogenesis. The virus is expressed in
neuroblastomas, but not in normal adrenal medulla, and
it colocalizes and binds to p53 [33]. The carcinogenic
mechanisms and properties of polyomaviruses (Table 1)
identify them as at least acting as cofactors in carcino-
genesis, especially in children who have immature im-
mune systems.
A growing number of studies on the herpes family of
viruses and on childhood CNS tumors show positive
correlations. Cytomegalovirus (CMV) was associated
with non-CNS cancers and CNS tumors, including me-
dulloblastoma, which is the most common CNS malig-
nancy in children. CMV DNA and proteins were
detected in primary medulloblastoma, in cell lines, and in
xenografts. Thirty-seven primary medulloblastoma cases
were examined, and 34 (92%) expressed immediate-early
proteins, and 27 (73%) expressed late viral proteins [63].
The virus and viral particles were also detected in glio-
blastoma multiforme (GBM), a rare tumor among chil-
dren [64]. Many CMV viral proteins inhibit apoptosis in
infected cells. At least six different proteins were associ-
ated with inhibition of apoptosis and could therefore en-
hance survival of CMV-infected tumor cells [27,28]. It was
reported that UL36 protein is responsible for chemother-
apy resistance of infected cells in vitro [29]. CMV was also
found to inhibit expression of HLA class I and class II
antigens and antigen presentation, and thus activation of
T-cells. CMV can also inhibit NK cell activation and
cytotoxicity [34].
Recently, the mechanisms of how particular infectious
agents contribute to carcinogenesis of CNS tumors were
discussed. Infections can include not only viruses, but
also bacteria and parasites [65]. It is obvious that adult
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ever, a scarcity of studies on the association of childhood
nervous sytem tumors with infectious agents limits the
understanding of the role of infectious agents. Therefore,
studies of how and to what extent viruses, bacteria, and
parasites can contribute to the development of child-
hood tumors are needed.
Rare cancers
There are many other types of benign and malignant tu-
mors which occur rarely in children. A case study of a
child diagnosed with both sialoblastoma and hepatoblas-
toma demonstrated elevated levels of procalcitonin, pro-
inflammatory stimulus to bacteria, and increased levels
of C reactive protein, suggesting a response against bac-
terial infections [66]. Sialoblastoma affects parotid glands
during infancy, and is rare, with only 24 cases reported
in MedLine (1990–2008). Hepatoblastoma originates in
the liver, and comprises less than 1% of reported tumors
among children from infancy to 3 years of age [67]. An-
other liver tumor, a hepatocellular carcinoma (HCC), is
also rare in children [68]. Hepatitis B virus (HBV) was
found to be responsible for HCC in children in Taiwan,
where HBV was endemic [69]. This relationship of HBV
and childhood cancer was established as a result of dis-
covering 100% HBsAg seropositivity among children
with HCC and HBV DNA in their neoplasms [69,70].
The role of HBV infection in the cause of hepatocellular
carcinoma is further confirmed when Taiwanese HBV
immunization programme significantly reduced the cancer
incidence in vaccinated children compared to non-
vaccinated children [71]. In addition to this, the twenty-
year study has shown lower incidence of HCC in those
Thai children who received HBV vaccine at birth [72].
Another infrequent type of childhood cancer is head
and neck cancers which include lesions on the lip, oral
cavity, nose and paranasal sinuses, naso-pharynx, oro-
pharynx, hypopharynx, and larynx [73]. It accounts for
5% of all childhood cancers [74]. Syrjanen et al. [75] first
reported the association of human papilloma virus
(HPV) infections in the oncogenesis of laryngeal and
oral cancers by observing similar morphological features
both in oral and cervical squamous cell lesions. A direct
oncogenic role of high risk HPV E6 and E7 proteins was
identified. The viral proteins bind and thereby inactivate
the tumor suppressors [32]. HPV probably employs the
same mechanism of cancer development in different age
groups, including children, and may act as an independ-
ent risk factor for oral cancer, another extremely rare
childhood cancer [76].
To continue, nasopharyngeal carcinoma (NPC) is a
rare cancer which occurs on the epithelium of the naso-
pharynx and accounts for about 1% of all childhood tu-
mors. According to WHO there are three subtypes ofNPC, including squamous cell carcinoma commonly
found in adults, non-keratinizing carcinoma, and undif-
ferentiated carcinoma. Childhood cancer cases are usu-
ally the latter subtype and EBV is involved in its
aetiology [77,78]. It was found that abundance of LMP1
expression of EBV protein correlated with a patient’s
age. There were higher levels of LMP1 in younger pa-
tients’ specimens in Tunisia (n = 22 out of 82) [79]. It
was in concordance with previous findings, where anti-
viral capsid antigen, early antigen IgG and IgA levels
were lower in juvenile form of NPC compared to adult
form [80,81]. NPC incidence is 1 per 100,000 children
diagnosed annually in the US whilst it is more common
in children of the Southeast Asia and Northern African
region, with 8–25 per 100,000 cases recorded annually
[82,83]. In Hong Kong 80% of children are infected by
6 years of age and almost 100% have seroconverted by
the age of 10 years [84]. The disclosure of the EBV nu-
clear antigen and viral DNA in the NPC demonstrated
that EBV can infect epithelial cells and is associated with
their malignant transformation.
Kaposi’s sarcoma (KS) is a tumor, which originates
from the cell lining of lymph or blood vessels. It is clas-
sified primarily into three types: classical, endemic and
epidemic. Classical KS is prevalent among elderly men;
whilst younger generation, located close to African equa-
tor, is prone to endemic KS, or African KS. Epidemic KS
occurs in patients with AIDS caused by HIV [85]. It is to
be noted that before the onset of HIV in 1985 KS had
been endemic in Africa [86]. It was reported that KS is
caused by Human Herpes Virus 8 (HHV-8, also known
as Kaposi sarcoma-associated herpesvirus) in children
whose immune system is weakened [87,88]. During the
period of AIDS infection the cases of childhood KS in-
creased more than 40-fold [89]. Prevalence of KS inci-
dence among children is higher in Africa, where both
HHV-8 and HIV are endemic, in contrast to well-
resourced states, where patients have access to antiretro-
viral therapy [87,90].
To sum up, the above-mentioned cancers are rare or
even extremely rare in children, and more studies are
needed to establish the mechanism of infection-based
cancer development. However, there is still space to sus-
pect the pathogens, which stimulate these rare malig-
nancies in young generation.
Possible mechanisms of childhood cancers
The mechanisms of infectious etiologies of CC have
been studied since the 1970s [91,92], yet a definitive as-
sociation has not been established for the majority of
childhood cancers. It is known that viruses such as
CMV, HPV, VZV, and HSV can cross the placenta and
infect the fetus. Various infections can also be acquired
during passage through the birth canal if the mother is
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observed that HPV and EBV are sometimes found in
breast milk and can be transmitted to the infant through
breastfeeding [93]. Some of the above mentioned viruses
are also found to cause tumors in adults (i.e., HPV in
the cervix and in anogenital cancers, human HHV-8 in
Kaposi’s sarcoma, and EBV in Burkitt’s lymphoma).
Many mechanisms are used by infectious agents to sur-
vive in a host and create favorable conditions for neo-
plastic transformation. It is also possible that a child can
inherit mutations that occurred in the germ cells of the
parents via viral mutagenesis. Partial sequences of HHV-
6A have been found in members of the same families
[36]. All of the mechanisms listed in Table 1 could be
exploited in combination, synergistically creating favorable
conditions for neoplastic lesions to develop. Disruption of
tumor suppression, in combination with apoptosis, im-
mune evasion, and low-grade inflammation could enhance
the accumulation of mutations, and this would select for
preneoplastic cells, which over time could lead to the de-
velopment of a tumor. Infants are born with an undevel-
oped immune system, and the prevalence of latent viral
infections in adults that come in contact with newborns
could facilitate the transmission of viruses. Thus, the
chance of latent infections is likely.
Hypothesis
There are several proposed theories for childhood cancer
development. Most theories focus on leukemia progres-
sion. One of them is the Greaves’ hypothesis of a “delayed
infection”. It states that a child’s immature immune sys-
tem requires early exposure to common infections for the
proper immune system maturation. The lack of it leads to
the aberrant response to infection. As evidence for the hy-
pothesis, there are examples of well protected babies from
developed countries (hygienic conditions), and they prone
to get childhood leukemia i.e. they had aberrant response
to delayed exposure to infectious agents [94]. Another hy-
pothesis, the Kinlen hypothesis, proposes that a common
infectious agent is responsible for increased leukemia
cases transmitted by adults during a large-scale rural–
urban population mixing [95]. Both Greaves and Kinlen
hypothesis are supported by epidemiological data which
accumulated over the past 15 years. They propose an un-
known infectious agent (mostly viral by Kinlen) that trig-
ger an aberrant immune response and thus can be a
causative agent of childhood ALL. A more recent unifying
hypothesis, of “cell transformation by replication-defective
mutants,” suggests that only viruses which have defects in
replication machinery show elevated transformation po-
tential, and when they are present in cells with certain
chromosomal translocations, it can lead to leukemia de-
velopment [96]. Finally, the “infective lymphoid recovery”
hypothesis proposes that infective stress, triggering theheat shock response in infancy, stimulates proinflamma-
tory cytokines and inhibits apoptosis. This, in turn, leads
to a decline in antitumor immunity and in B-cell matur-
ation arrest. This hypothesis addresses the infection para-
dox stated in Greaves’ and Kinlen’s hypotheses, that an
unhygienic environment primes the adaptive immune re-
sponse and is protective against childhood ALL, while
multiple infections occurring later increase the risk of
childhood ALL [97]. Overall, it is proposed that infection
can be a triggering mechanism, and most likely, the im-
munological state, genetic alterations, and infections have
a cumulative effect on leukemia development, and pos-
sibly on the development of other cancer types.Conclusions
The etiology of childhood cancers still remains unknown.
In addition to genetic and environmental factors, we have
shown that infectious agents also play a significant role in
cancer development. These include human herpesviruses
(especially EBV, CMV, and HHV-6), polyomaviruses
(SV40, JCV, and BKV), HPV, HIV, HCV, and H. pylori.
These infectious agents can be controlled by treatment
and/or vaccination. It was shown that, using immune
globulins during pregnancy and after birth, some protect-
ive effect against some herpes viruses and HBV [98-100]
was observed. Vaccines may also protect against mother-
to-child transmission of infections [101]. Because the
elimination of infection could minimize the risk of child-
hood cancer, everything possible should be done to pre-
vent or control infections in both the mother and child.
Sanitary measures and regulations can help to reduce the
occurrence of such infections during pregnancy, the first
years of life, and in healthcare institutions. Early diagnosis
should also be improved and included in family planning
programs. If the infections are already present or at high
risk, more treatments should be done to prevent mother-
to-child transmission, with specific attention focused on
the development of safer vaccines and therapeutics [102].
Information on possible risks and proper counseling
should be available to susceptible populations. However,
there is still insufficient clinical data to provide a complete
plan to reduce the risks of infection-driven cancers in
children.
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